| Phenotypes in acute respiratory distress syndrome: moving towards precision medicine |
21 |
| Defining anabolic resistance: implications for delivery of clinical care nutrition |
21 |
| Lessons to learn from epidemiologic studies in ARDS |
16 |
| Diaphragm-protective mechanical ventilation |
15 |
| Sepsis-induced myocardial dysfunction |
14 |
| Cardiac output monitoring: how to choose the optimal method for the individual patient |
14 |
| Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia |
13 |
| Continuous renal replacement therapy during extracorporeal membrane oxygenation: why, when and how? |
13 |
| Measuring and monitoring lean body mass in critical illness |
12 |
| Assessment of fluid responsiveness: recent advances |
12 |
| Long-term outcome after the acute respiratory distress syndrome: different from general critical illness? |
11 |
| Vitamin C: should we supplement? |
11 |
| Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria |
11 |
| Understanding patient-important outcomes after critical illness: a synthesis of recent qualitative, empirical, and consensus-related studies |
11 |
| An update on membranes and cartridges for extracorporeal blood purification in sepsis and septic shock |
11 |
| Drug-induced acute kidney injury: diverse mechanisms of tubular injury |
11 |
| Epidemiology of ICU-acquired pneumonia |
10 |
| CRRT for sepsis-induced acute kidney injury |
10 |
| Inotropes and vasopressors use in cardiogenic shock: when, which and how much? |
10 |
| Inflammatory processes during acute respiratory distress syndrome: a complex system |
10 |
| Monitoring peripheral perfusion and microcirculation |
9 |
| Refeeding syndrome: relevance for the critically ill patient |
8 |
| Community-acquired pneumonia as an emergency condition |
8 |
| Safety of vitamin C in sepsis: a neglected topic |
8 |
| Assessment of microcirculation in cardiogenic shock |
8 |
| The microbiome of the critically ill patient |
8 |
| Artificial liver support in acute and acute-on-chronic liver failure |
7 |
| Impact of spontaneous breathing during mechanical ventilation in acute respiratory distress syndrome |
7 |
| Whole-body computed tomography in severely injured patients |
7 |
| New physiological insights in ventilation during cardiopulmonary resuscitation |
7 |
| Understanding the carbon dioxide gaps |
7 |
| Regional citrate anticoagulation for continuous renal replacement therapy |
7 |
| Extravascular lung water measurements in acute respiratory distress syndrome: why, how, and when? |
6 |
| New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe |
6 |
| Continuous or intermittent feeding: pros and cons |
6 |
| Mechanical circulatory devices in acute heart failure |
6 |
| The role of frailty and prehabilitation in surgery |
6 |
| Feeding should be individualized in the critically ill patients |
6 |
| Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together |
6 |
| Population enrichment for critical care trials: phenotypes and differential outcomes |
6 |
| The microbiome and nutrition in critical illness |
6 |
| Is it time to abandon glucose control in critically ill adult patients? |
5 |
| Venoarterial extracorporeal membrane oxygenation in cardiogenic shock: indications, mode of operation, and current evidence |
5 |
| Severe influenza: overview in critically ill patients |
5 |
| Assessing brain injury after cardiac arrest, towards a quantitative approach |
5 |
| Prehospital termination of resuscitation rule |
5 |
| Hemodynamic monitoring in the extracorporeal membrane oxygenation patient |
5 |
| Long-term outcome following decompressive craniectomy: an inconvenient truth? |
5 |
| From dysmotility to virulent pathogens: implications of opioid use in the ICU |
5 |
| Esophageal pressure monitoring: why, when and how? |
4 |
